## David S Corcoran

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/22552/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina. Journal of the American College of Cardiology, 2018, 72, 2841-2855.	1.2	436
2	1-Year Outcomes of Angina Management Guided by Invasive Coronary Function Testing (CorMicA). JACC: Cardiovascular Interventions, 2020, 13, 33-45.	1.1	141
3	Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need. Heart, 2018, 104, 284-292.	1.2	86
4	Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction. European Heart Journal, 2020, 41, 3239-3252.	1.0	73
5	Fractional flow reserve-guided management in stable coronary disease and acute myocardial infarction: recent developments. European Heart Journal, 2015, 36, 3155-3164.	1.0	58
6	Single―Versus 2â€Stent Strategies for Coronary Bifurcation Lesions: A Systematic Review and Metaâ€Analysis of Randomized Trials With Longâ€Term Followâ€up. Journal of the American Heart Association, 2018, 7, .	1.6	53
7	Diagnosis of patients with angina and non-obstructive coronary disease in the catheter laboratory. Heart, 2019, 105, 1536-1542.	1.2	53
8	Coronary microvascular dysfunction in patients with stable coronary artery disease: The CE-MARC 2 coronary physiology sub-study. International Journal of Cardiology, 2018, 266, 7-14.	0.8	41
9	A multisystem, cardio-renal investigation of post-COVID-19 illness. Nature Medicine, 2022, 28, 1303-1313.	15.2	39
10	The Chief Scientist Office Cardiovascular and Pulmonary Imaging in SARS Coronavirus disease-19 (CISCO-19) study. Cardiovascular Research, 2020, 116, 2185-2196.	1.8	31
11	The right ventricular response to lung resection. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 556-565.e5.	0.4	26
12	Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial. American Heart Journal, 2018, 201, 86-94.	1.2	22
13	Risk stratification in non-ST elevation acute coronary syndromes: Risk scores, biomarkers and clinical judgment. IJC Heart and Vasculature, 2015, 8, 131-137.	0.6	21
14	Fractional flow reserve: a clinical perspective. International Journal of Cardiovascular Imaging, 2017, 33, 961-974.	0.7	19
15	Invasive Versus Medical Management in Patients With Prior Coronary Artery Bypass Surgery With a Non-ST Segment Elevation Acute Coronary Syndrome. Circulation: Cardiovascular Interventions, 2019, 12, e007830.	1.4	17
16	New perspectives on the role of cardiac magnetic resonance imaging to evaluate myocardial salvage and myocardial hemorrhage after acute reperfused ST-elevation myocardial infarction. Expert Review of Cardiovascular Therapy, 2016, 14, 843-854.	0.6	14
17	Coronary microvascular disease: the next frontier for Cardiovascular Research. Cardiovascular Research, 2020, 116, 737-740.	1.8	13
18	Percutaneous coronary intervention versus medical therapy in patients with angina and grey-zone fractional flow reserve values: a randomised clinical trial. Heart, 2020, 106, 758-764.	1.2	13

## DAVID S CORCORAN

#	Article	IF	CITATIONS
19	Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABC-ACS). Open Heart, 2016, 3, e000371.	0.9	7
20	Inhibition of myocardial cathepsin-L release during reperfusion following myocardial infarction improves cardiac function and reduces infarct size. Cardiovascular Research, 2022, 118, 1535-1547.	1.8	6
21	MINOCA: Requirement for Definitive Diagnostic Work-Up. Heart Lung and Circulation, 2019, 28, e4-e6.	0.2	3
22	Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial. Cardiovascular Research, 2021, 117, 320-329.	1.8	3
23	Magnetic Resonance Perfusion Imaging to Guide Management of Patients With Stable Ischemic Heart Disease. JACC: Cardiovascular Imaging, 2018, 11, 997-999.	2.3	2
24	Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populations. Open Heart, 2021, 8, e001453.	0.9	2
25	Cardiovascular health technology assessment: recommendations to improve the quality of evidence. Open Heart, 2019, 6, e000930.	0.9	1
26	Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populations. Open Heart, 2021, 8, .	0.9	1
27	Is it important to differentiate between peri-procedural myocardial injury and persistent myocardial scar?. Journal of Thoracic Disease, 2018, 10, E830-E831.	0.6	0
28	9â€Routine non-invasive vs invasive management in patients with prior CABG with a NSTE-ACS: a randomised controlled trial. , 2018, , .		0
29	5â€Effect of remote ischaemic preconditioning on coronary artery function in patients with stable coronary artery disease. , 2018, , .		0